A

mazon’s ambitions in health care are now clear: It not only wants to fundamentally change treatment of U.S. patients, it wants a large chunk of the $370 billion market for selling and distributing their prescription drugs.

The company’s acquisition of the home delivery pharmacy PillPack is entirely separate from its venture with JPMorgan Chase and Berkshire Hathaway to improve and lower the cost of care for the companies’ 1 million employees.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy